Anti-Human B7-1 (CD80)

Purified Recombinant Human B7-1 (>98%) (Accession # P33681)

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

IHC (NBF/Par.): This antibody should give satisfactory staining results when used at a concentration of 25 µg/ml. The recommended secondary antibody for IHC is PN:M114. For chromogenic detection with high signal and low background use PN:D100 or PN:K107.
Neutralization: This antibody is useful for neutralization of Human B7-1 bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human B7-1 (at 0.1 µg/ml) is 0.001 - 0.002 µg/ml.
CyTOF-ready: Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Clone 37711 recognizes an epitope on human CD80.

CD80 is expressed on activated B cells, monocytes/macrophages, and dendritic cells.

CD80 is a highly glycosylated 60 kD protein that is part of the Ig superfamily and is significantly involved in immune cell activation in response to pathogens. CD80 is closely related to, and works in tandem with CD86 (B7-2) to prime T- cells. CD80 binds to CTLA-4 to deliver an inhibitory signal to T cells. The ligation of CD28 on T cells with CD80 and CD86 on APCs co-stimulates T cells resulting in enhanced cell activation, proliferation, and cytokine production. It is thought that CD80 interacts with a ligand on Natural Killer cells, activating the Natural Killer cell-mediated cell death of the CD80 carrier. The activation of Natural Killer cell-mediated death via CD80 interactions has potential as a possible cancer immunotherapy through the induction of CD80 expression on tumor cells.